Cargando…

Guillain-Barre syndrome in 220 patients with COVID-19

This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers....

Descripción completa

Detalles Bibliográficos
Autores principales: Finsterer, Josef, Scorza, Fulvio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094972/
https://www.ncbi.nlm.nih.gov/pubmed/33967575
http://dx.doi.org/10.1186/s41983-021-00310-7
_version_ 1783688009796812800
author Finsterer, Josef
Scorza, Fulvio A.
author_facet Finsterer, Josef
Scorza, Fulvio A.
author_sort Finsterer, Josef
collection PubMed
description This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers. SC2-GBS is most likely secondary due to an immune reaction against SARS-CoV-2 since the virus has not been found in the CSF of any SC2-GBS patient so far reported. SC2-GBS occurs in each age group and does not differ from non-SC2-GBS regarding clinical presentation and treatment, but the outcome of SC2-GBS is worse compared to non-CS2-GBS patients, and the prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Early diagnosis of SC2-GBS is warranted to apply appropriate treatment in due time and to improve the overall outcome from the infection.
format Online
Article
Text
id pubmed-8094972
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80949722021-05-05 Guillain-Barre syndrome in 220 patients with COVID-19 Finsterer, Josef Scorza, Fulvio A. Egypt J Neurol Psychiatr Neurosurg Review This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers. SC2-GBS is most likely secondary due to an immune reaction against SARS-CoV-2 since the virus has not been found in the CSF of any SC2-GBS patient so far reported. SC2-GBS occurs in each age group and does not differ from non-SC2-GBS regarding clinical presentation and treatment, but the outcome of SC2-GBS is worse compared to non-CS2-GBS patients, and the prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Early diagnosis of SC2-GBS is warranted to apply appropriate treatment in due time and to improve the overall outcome from the infection. Springer Berlin Heidelberg 2021-05-04 2021 /pmc/articles/PMC8094972/ /pubmed/33967575 http://dx.doi.org/10.1186/s41983-021-00310-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Finsterer, Josef
Scorza, Fulvio A.
Guillain-Barre syndrome in 220 patients with COVID-19
title Guillain-Barre syndrome in 220 patients with COVID-19
title_full Guillain-Barre syndrome in 220 patients with COVID-19
title_fullStr Guillain-Barre syndrome in 220 patients with COVID-19
title_full_unstemmed Guillain-Barre syndrome in 220 patients with COVID-19
title_short Guillain-Barre syndrome in 220 patients with COVID-19
title_sort guillain-barre syndrome in 220 patients with covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094972/
https://www.ncbi.nlm.nih.gov/pubmed/33967575
http://dx.doi.org/10.1186/s41983-021-00310-7
work_keys_str_mv AT finstererjosef guillainbarresyndromein220patientswithcovid19
AT scorzafulvioa guillainbarresyndromein220patientswithcovid19